top of page

SUBSCRIBE TO OUR NEWSLETTER

THE LATEST NEWS IN CANCER CLINICAL RESEARCH

AT MEDSIR WE ARE DEDICATED TO OFFER THE MOST RELEVANT NEWS ON THE LATEST ADVANCEMENTS IN ONCOLOGY CLINICAL RESEARCH. FIND OUT THE LATEST NEWS ON ONCOLOGY RESEARCH, REGULATORY APPROVALS, EVENTS, SCIENTIFIC CONFERENCES AND MUCH MORE!

DOWNLOAD COMPANY DOSSIER

Search

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

May 304 min read

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

Apr 222 min read

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

Feb 264 min read

MEDSIR strengthens its commitment to information security and privacy

MEDSIR strengthens its commitment to information security and privacy

MEDSIR strengthens its commitment to information security and privacy

Feb 191 min read

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

CANCER RESEARCH

Dec 23, 20245 min read

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Dec 12, 20247 min read

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

Dec 5, 20245 min read

MEDSIR Academy: Shaping the Future of Oncology Clinical Research

MEDSIR Academy: Shaping the Future of Oncology Clinical Research

MEDSIR Academy: Shaping the Future of Oncology Clinical Research

Nov 25, 20243 min read

MEDSIR joins the IGCS 2024 annual meeting: expanding horizons towards gynecologic oncology

MEDSIR joins the IGCS 2024 annual meeting: expanding horizons towards gynecologic oncology

MEDSIR joins the IGCS 2024 annual meeting: expanding horizons towards gynecologic oncology

Oct 31, 20243 min read

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

Oct 23, 20244 min read

Highlights from ESMO 2024: The Next Frontier in Oncology

Highlights from ESMO 2024: The Next Frontier in Oncology

Highlights from ESMO 2024: The Next Frontier in Oncology

Sep 25, 20244 min read

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Sep 20, 20244 min read

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

Sep 16, 20245 min read

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Sep 13, 20246 min read

Highlights from the SNO/ASCO CNS Metastases Conference: unveiling new frontiers in cancer brain metastasis

Highlights from the SNO/ASCO CNS Metastases Conference: unveiling new frontiers in cancer brain metastasis

Highlights from the SNO/ASCO CNS Metastases Conference: unveiling new frontiers in cancer brain metastasis

Aug 14, 20243 min read

Integration of Artificial Intelligence in Oncology Research

Integration of Artificial Intelligence in Oncology Research

Integration of Artificial Intelligence in Oncology Research

Jul 18, 20242 min read

National Cancer Survivor Month

National Cancer Survivor Month

National Cancer Survivor Month

Jun 13, 20243 min read

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

Jun 3, 20244 min read

Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

May 29, 20243 min read

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

May 28, 20244 min read

Bridging science to care: insights on translational studies and our presence at AACR Congress 2024

Bridging science to care: insights on translational studies and our presence at AACR Congress 2024

Bridging science to care: insights on translational studies and our presence at AACR Congress 2024

Apr 18, 20243 min read

A Recap of the Think Tank Meeting in Breast Cancer in São Paulo, Brazil

A Recap of the Think Tank Meeting in Breast Cancer in São Paulo, Brazil

A Recap of the Think Tank Meeting in Breast Cancer in São Paulo, Brazil

Apr 15, 20242 min read

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

Apr 9, 20243 min read

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

Apr 4, 20243 min read

2 3 4 5

bottom of page